% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Feb 1, 2013 7:33 PM Flag

    Reasons to expect good price action next week.

    First of all, Long posted a paper today that shows that CDX-110 is a superior brain cancer drug.
    Second, sometime in Feb Celldex will submit abstract(s) to ASCO.
    Third, we are getting ever closer to the CC where investors will finally hear about the phase 3 design for CDX-011.
    We may also hear something about the dense deposit disease trial.
    I expect heavy buying, perhaps even from the investors who had a private presentation with Celldex last month. Do not be surprised to see the SP hit $8 next week.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Accelerated approval is very good news.

      Sentiment: Strong Buy

    • DCVax-001 – HIV Vaccine: Celldex and Rockefeller University investigators are collaborating on an effort to develop a vaccine against HIV, the virus known to cause AIDS. The Rockefeller vaccine, called DCVax-001, is an APC-targeted vaccine consisting of a fusion protein of a human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program has been funded through a grant from the Bill & Melinda Gates Foundation. The vaccine is currently being tested in a Phase 1 trial in healthy volunteers at Rockefeller University.

      Sentiment: Strong Buy

    • Celldex is teamed up with Rockefeller University on this study. Results coming in May.
      DCVax Plus Poly ICLC in Healthy Volunteers
      DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.

      Estimated Enrollment: 45
      Study Start Date: May 2010
      Estimated Study Completion Date: May 2013
      Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

      Sentiment: Strong Buy

      • 1 Reply to weightbayou
      • I would be very surprised on major positive developments on this one. This is virtually the only one in the entire vast pipeline that we have heard nothing on since its inception. Therefore, I would be rather shocked, barring spectacular news, probably they will spin off/sell this entirely, too many smoking hot irons in the fire

    • did you mention the FDA conditional approval which is possible too....?

      Sentiment: Buy

      • 3 Replies to optical333
      • Don't forget partnership deal potential at any time for CDX-011 and/or Rindo outside US. Maybe not this week, but we've been waiting a long time, so it could come to fruition this coming week.

        Sentiment: Strong Buy

      • If we got FDA conditional approval that would be huge beyond belief. I am still wondering why Celldex is looking for a Director of Marketing at this time. That is interesting to say the least. Plus, the secret investor meeting that occurred last month. Things are going on beyond the scenes. Yes. FDA conditional approval could be coming.

        Sentiment: Strong Buy

      • This is a very good point- according to a fda rule change last year, if a drug does particularly well in phase II trials, and there are no good current treatment options, they can get approved just on the basis of the phase II trials- To me anyways, cdx-011 would appear TAYLOR MADE for an approval like that!!

    • Also in early April: New Cancer Vaccines
      Chairperson: Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA

      Cornelis J. M. Melief, Leiden University Medical Center, Leiden, The Netherlands
      Thomas A. Davis, Celldex Therapeutics, Clarksville, MD
      Harpreet Singh-Jasuja, Universität Tübingen, Tübingen, Germany
      Glenn Dranoff

      Finally, do not forget Black Rock has a large stake in CLDX. Selling early without needing the money is dangerous imo. Have a great weekend!

      Sentiment: Strong Buy

3.36+0.02(+0.60%)Oct 24 4:00 PMEDT